An electronic surveillance network for monitoring antibiotic resistance in The Netherlands has been in operation since 1989. Seven public health laboratories participate and the system covers about 25% of all bacteriological determinations in The Netherlands. This paper reports the results of staphylococci isolated in the period 1989-1995. About 0.3% of the Staphylococcus aureus isolates in the study period were resistant to methicillin. This low percentage may be due to the restrictive use of antibiotics and to strict isolation measures aimed at eradicating methicillin-resistant S. aureus. Low frequencies of resistance among methicillin-resistant S. aureus were found for vancomycin (0%), chloramphenicol (11%), cotrimoxazole (11%), mupirocin (3% low-level resistance) and fusidic acid (7%). Twenty-one percent of the coagulase-negative staphylococci were resistant to methicillin. Low frequencies of resistance among these methicillin-resistant coagulase-negative staphylococci were those to vancomycin (0.4%), nitrofurantoin (2%), doxycycline (20%) and amikacin (20%). Coagulase-negative staphylococci from cerebrospinal fluid, blood and skin were less often resistant to quinolones than isolates from respiratory tract, faeces and urine. A significant increase in resistance of coagulase-negative staphylococci to methicillin, erythromycin, gentamicin and ciprofloxacin was observed in the investigated period but the resistance to doxycycline and co-trimoxazole decreased in the last few years. To confirm the determination of methicillin resistance and coagulase production, a PCR method was developed which detects both the mecA and the coagulase gene. The results of the PCR method correlated well with the methicillin MIC as determined by an agar-dilution method.
Introduction
The prevalence of methicillin-resistant Staphylococcus aureus differs widely among countries. 1 In US hospitals the percentage of S. aureus resistant to methicillin rose from 2.4% in 1975 to 29% in 1991. 2 In Europe the percentage of S. aureus resistant to oxacillin ranged from 0.1-0.3% in Denmark and Sweden to 30% in Spain, France and Italy. 3 The Dutch laboratories participating in that study reported a resistance frequency of 1.5%.
Although methicillin-resistant S. aureus has caused most concern, drug-resistant coagulase-negative staphylococci are an increasing problem, especially in the treatment of critically ill patients in intensive care units. 4, 5 In the USA 75% of Staphylococcus epidermidis and 48% of other coagulase-negative staphylococci were found to be resistant to methicillin or oxacillin. 6 Methicillin-resistant coagulase-negative staphylococci were often co-resistant to other antibiotics. 7 To monitor the prevalence of drug resistance in The Netherlands, a nationwide electronic system for surveillance of bacterial drug resistance was implemented in 1989. This system covers approximately 25% of all susceptibility tests done in Dutch laboratories. Since 1989, all labora-
Materials and methods

The surveillance network
The surveillance network was started in 1989, when five laboratories took part. Since 1990 seven public health laboratories, at Enschede, Tilburg, Leeuwarden, Haarlem, Rotterdam, , Goes and Nijmegen, have sent all routine susceptibility testing data to the RIVM. Although the methods of susceptibility testing varied among the participating laboratories, each complied with the criteria of the Dutch Committee on Antibiotic Susceptibility Guidelines. 8 In addition to the species name of the isolated microorganisms and their susceptibility to each of the antibiotics tested, the sample site (urine, blood, etc.) was reported as well as the date of birth, gender and residence of the patient. The results were saved on floppy disks in a standardized ASCII format and sent to the RIVM. The susceptibility results were not interpreted by the sending laboratory. Each year the participating laboratories received a report of the results of all participants. If an isolate of the same bacterial species was sampled from the same patient within 2 months after the first isolate, this isolate was considered as a duplicate and ignored.
Susceptibility testing in the central laboratory
Since 1989 the laboratories in The Netherlands have sent all isolates of S. aureus resistant to methicillin or oxacillin to the RIVM. The antibiotic susceptibility of each isolate was determined at the RIVM by an agar-dilution method using the guidelines of the Dutch Committee on Antibiotic Susceptibility Guidelines.
Amikacin was obtained from Bristol-Myers Squibb Co. (Syracuse, NY, USA), chloramphenicol, neomycin, rifampicin, sulphamethoxazole and trimethoprim from Sigma Chemical Co. (St Louis, MO, USA), ciprofloxacin from Bayer AG (Wuppertal-Elberfeld, Germany), clindamycin from Upjohn SA (Puurs, Belgium), erythromycin from Abbott Laboratories Ltd (Queenborough, Kent, UK), fusidic acid from Leo Pharmaceuticals (Ballerup, Denmark), gentamicin from Schering-Plough Products Inc. (Brussels, Belgium), methicillin and mupirocin from SmithKline Beecham Pharma (Rijswijk, The Netherlands), tetracycline from Serva (Heidelberg, Germany) and vancomycin from Eli Lilly (Indianapolis, USA).
The susceptibility to methicillin was tested using an inoculum of 5 10 5 cfu/spot on Mueller-Hinton agar and incubation at 30°C for 24 h. The susceptibility to other antibiotics was tested using an inoculum of For comparison with the developed PCR method, the methicillin resistance of consecutive isolates of coagulasenegative staphylococci received from three local laboratories was determined at 37°C on Mueller-Hinton agar for 24 h. This temperature was used because coagulasenegative staphylococci grew better at 37°C than at 30°C.
PCR detection of the coagulase and mecA genes in staphylococci
Template DNA for PCR was obtained from 1 mL of an overnight culture of staphylococci grown in Tryptone Soya Broth (Oxoid). Cells were spun and washed once in 1 mL of TE (10 mM Tris-HCl, 1 mM EDTA, pH 7.0), resuspended in 50 L of lysis mix (200 mg/L lysostaphine, 10 mM Tris-HCl, 1 mM EDTA, pH 7.0), incubated for 30 min at 37ºC and lysed by heating for 10 min at 99ºC. This crude lysate was either used directly in the PCR or stored at 20ºC for later use.
The coagulase and mecA genes in staphylococci were detected using multiplex PCRs. Two PCR protocols were developed. The first PCR was used to detect the coagulase gene in methicillin-resistant S. aureus. This PCR used a primer set, primers Coa6m13 (TGTAAAACGACG-GCCAGTGTACAGGTATCCGTGAATA, residues 1444-1462) and Coa7m13 (CAGGAAACAGCTAT-GACCTTGACTGTATGTCTTTGGA, residues 1924-1942), specific for the coagulase gene (GenBank accession number X17679). The underlined sequences denote M13-specific forward and reverse sequences. Another primer set, primers MecAI (GTTGTAGTTGTCGGGTTTGG, residues 36-55) and MecAC3 (CTTCCACATAC-CATCTTCTTTAAC, residues 348-371), allowed amplification of the mecA gene (GenBank accession number X52593). The coagulase gene primers were used to check for the presence of S. aureus DNA and for the absence of PCR inhibitors. Methicillin-sensitive S. aureus isolates yield only one PCR product (the 499 bp coa amplicon) while methicillin-resistant S. aureus yields two PCR products, the 499 bp coa and the 336 bp mecA amplicon.
The PCR conditions were as follows: 2 L of the lysate, diluted 1 in 10 in TE, were added to 25 L of reaction mixture containing 10 pmol of primers MecAI and MecAC3 and 40 pmol of primers Coa6m13 and Coa7m13, 0.5 U of SuperTth DNA polymerase (HT Biotechnology Ltd, Cambridge, UK), 200 M of each dNTP, 50 mM Tris-HCl pH 9.0, 50 mM KCl, 1.5 mM MgCl 2 , 0.01% gelatin and 0.1% Triton X-100. A 50 L overlay of sterile mineral oil was added to each tube. A 'touch-down' PCR program 9 was used consisting of a 3 min denaturation step at 95ºC, a 1 min touch-down from 65ºC to 55ºC followed by 20 cycles of amplification of 1 min at 95ºC, 1 min at 55ºC and 1 min at 72ºC.
A second multiplex PCR was developed to detect the mecA gene in coagulase-negative staphylococci. In this PCR a 16S rRNA primer pair, primers 16S8F (AGAGTTTGATCCTGGCTCAG, residues 8-27 (Escherichia coli)) and 16S806R (GGAACCAGGG-TATCTAATCC, residues 785-806 (E. coli)) was used to check for the presence of bacterial DNA and the absence of polymerase inhibitors. All other reaction conditions were identical to those used in the PCR for methicillin-resistant S. aureus.
Statistical methods
Trends in resistance percentages were analysed using the procedure LOGISTIC of SAS.
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Results
Drug resistance of S. aureus
During the study period, a total of 89,573 S. aureus isolates were tested by the participating laboratories. The number of susceptibility tests for each antibiotic differed because the panel of tested antibiotics differed between the laboratories. The results of the surveillance are shown in Table I .
Seventy-eight percent of the S. aureus isolates were resistant to penicillin. The percentage of methicillin-resistant S. aureus was 0.3%. Resistance to doxycycline (2.1%) was lower than resistance to tetracycline (7.6%). Cotrimoxazole (0.6% resistance) was active against a higher proportion of isolates than trimethoprim or sulphamethoxazole alone. Of the quinolones, ciprofloxacin showed the lowest resistance (2.6%). Resistance to erythromycin, nitrofurantoin, rifampicin, fusidic acid and vancomycin was low or negligible. Methicillin-resistant S. aureus were most often susceptible to vancomycin (0% resistance), nitrofurantoin (3%) and co-trimoxazole (16%).
Epidemiology of methicillin-resistant S. aureus in The Netherlands
Since 1989, all laboratories in The Netherlands have sent all methicillin-resistant S. aureus isolates to the RIVM for phage typing and confirmation of susceptibility testing. The number of isolates from patients and personnel (one isolate per person) ranged from 136 to 215 per year. Eighty percent of the isolates were from hospitalized patients; the remainder were cultures from healthcare workers examined for carriage. Four hundred and eighty-nine (39%) of the isolates were from individuals with no known epidemiological connection to other individuals harbouring methicillin-resistant S. aureus. These isolates comprised 218 different phage types. The remaining 760 isolates (61%) were from 97 hospital outbreaks. In these outbreaks two or more isolates were recovered sharing one of 67 phage types. The number and the size of the outbreaks is given in Figure 1 . Twenty-three percent of the isolates were from outbreaks of two to ten isolates, 38 percent belonged to outbreaks of more than ten isolates. Sixty percent of the methicillin-resistant S. aureus isolates were from patients transferred from foreign hospitals, or were epidemiologically related to such patients.
Resistance spectrum of methicillin-resistant S. aureus isolates as tested by the central laboratory Table II shows the resistance spectrum of the methicillinresistant S. aureus isolates received by the central laboratory from all laboratories in The Netherlands. The antibiotics showing the lowest mean percentage of resistance were vancomycin (0%), mupirocin (3%), fusidic acid (7%), chloramphenicol (11%) and co-trimoxazole (11%). Logistic regression was applied to detect trends in the period 1989-1994. The resistance to ciprofloxacin, clindamycin and neomycin increased significantly, while the resistance to gentamicin and tetracycline showed a decreasing trend. Although an increasing percentage of isolates appeared resistant to fusidic acid during 1991-1993, the number remained low. Three percent of the strains isolated in 1992 and 9% in 1993 showed intermediate resistance to mupirocin (MIC 8-32 mg/L). These isolates were related to a single hospital outbreak. No high-level resistance to mupirocin (MIC 32 mg/L) was observed.
We investigated whether methicillin-resistant S. aureus isolates with particular resistance phenotypes were more related to outbreaks than other isolates (Table III) . Methicillin-resistant S. aureus isolates resistant to gentamicin were more often present in large outbreaks, but resistance to amikacin, chloramphenicol, co-trimoxazole and neomycin was significantly less common.
Comparison of the presence of mecA and methicillin MIC
The presence of the mecA gene was tested by PCR using 274 S. aureus strains and 40 coagulase-negative isolates (Table IV) . The mecA gene was detected in all isolates with an MIC of 16 mg/L However, of the strains with a methicillin MIC of 8 mg/L, six out of 23 S. aureus and one coagulase-negative strain were mecA-positive. 
Drug resistance of coagulase-negative staphylococci
The seven participating laboratories reported the drug resistance of 37,505 coagulase-negative staphylococci (one isolate per patient). Compared with S. aureus, coagulasenegative staphylococci were more often resistant to a number of antibiotics, 21% to methicillin, 25% to cotrimoxazole, 26% to gentamicin and 28% to ciprofloxacin (Table I) . Antibiotics showing the lowest resistance percentages against the coagulase-negative isolates were vancomycin (0.3% resistance), fusidic acid (1%), nitrofurantoin (2%), rifampicin (2%) and doxycycline (9%). The prevalence of resistance of coagulase-negative staphylococci to quinolones varied with the sample site ( Figure 2 ). Quinolone resistance was less frequent among isolates from cerebrospinal fluid, blood and skin, and more frequent in isolates from urine, respiratory tract and faeces. No such difference was found for other antibiotics. As shown in Figure 3 , the resistance to methicillin, gentamicin, erythromycin and ciprofloxacin increased during the 7 year observation period (P 0.0001 for linear trend in logistic regression). The resistance to doxycycline and co-trimoxzole increased in the first 4-5 years and decreased in the last years of the study period (P 0.0001 for linear and quadratic trend combined). Methicillin-resistant coagulase-negative staphylococci were often susceptible to vancomycin (0.4% resistance), nitrofurantoin (2%), doxycycline (20%) and amikacin (20%) ( Table I) .
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Discussion
The data collected in our study show that all commonly used antibiotics except -lactamase-sensitive penicillins remain useful in the treatment of S. aureus infections in The Netherlands. The lower resistance of doxycycline compared with tetracycline, 11 and of ciprofloxacin compared with norfloxacin, 12 may be explained by the higher intrinsic acitivity of the former antibiotics against S. aureus.
The percentage of methicillin resistance in S. aureus in the seven regional laboratories was very low, 0.3%, consistent with earlier results. 3, 13 Similar low percentages of methicillin-resistant S. aureus have been reported in other Northern European countries, for example 0.5% in Denmark 14 and 0.6% in the UK. 15 In contrast, the percentage of methicillin-resistant S. aureus was 5.5% in Germany, 3 14% (range: 0-70%) in Belgium, 16 and 34% in France and Italy. 3 Import of methicillin-resistant S. aureus is a major threat for a low prevalence country such as The Netherlands. Indeed we found that 60% of the methicillin-resistant S. aureus isolates were related directly or indirectly to patients transferred from hospitals abroad. Despite the relatively small number of methicillin-resistant S. aureus isolates in The Netherlands, the majority (61%) of the isolates were from outbreaks, some of which were large, comprising up to 63 isolates. This confirms the results of earlier studies in individual hospitals or nursing homes. 17, 18 The low prevalence of methicillin-resistant S. aureus in The Netherlands is probably due to the effectiveness of measures to contain emerging methicillin-resistant S. aureus in hospitals and nursing homes. Indeed strict hygienic measures to limit the transmission of methicillinresistant S. aureus have been implemented in all hospitals 19, 20 including isolation and screening of patients from foreign hospitals 21 and treatment of carriers. 17 Surprisingly we found that methicillin-resistant S. aureus isolates belonging to larger outbreaks were less often resistant to co-trimoxazole (2%) and chloramphenicol (2%) compared with isolates from small outbreaks (17-19%) . The same trend was observed for amikacin and neomycin. In contrast, gentamicin resistance was found more frequently among methicillin-resistant S. aureus in larger outbreaks (85%) than in small ones (70-72%). Whether these differences are related to antibiotic use or to differences in fitness is not clear.
This study showed that although methicillin-resistant S. aureus isolates are still rare in The Netherlands, they are often multi-resistant, as found in earlier surveys. 22 Resistance of methicillin-resistant S. aureus to co-trimoxazole is still relatively low in The Netherlands (11-15%). Therefore, co-trimoxazole may still be used in combination with fusidic acid ointment to eradicate methicillin-resistant S. aureus from carriers. 23, 24 Ciprofloxacin resistance among methicillin-resistant S. aureus isolates is increasing (Table II) , maybe due to increased use of quinolones. 23 In contrast, the frequency of resistance to doxycycline and co-trimoxazole has decreased in the last 2-3 years, possibly due to reduced use of these drugs in hospitals. ( , 1989; , 1990; , 1991; , 1992; , 1993; , 1994; , 1995 ).
Co-trimoxazole
The in-vitro activity of penicillin and co-amoxiclav against some methicillin-resistant S. aureus may be due to their higher intrinsic activity compared with methicillin, which may be clinically significant. 25 Because the MICs of methicillin for clinical isolates of S. aureus cover the whole concentration range from sensitive to resistant, the cut-off value for resistance is sometimes difficult to estimate by sensitivity testing. Therefore a PCR method was used to detect the coagulase and mecA genes in staphylococci. A good correlation was found between the PCR of the mecA gene and agar-dilution MIC using a high inoculum of S. aureus and coagulase-negative staphylococci.
Compared with S. aureus, coagulase-negative staphylococci were more often resistant to a broad range of antibiotics. Our results are similar to those of Mouton et al. 26 who found 24% resistance to methicillin in Dutch isolates of coagulase-negative staphylococci. However, we observed a clear increase in the resistance of coagulasenegative staphylococci to methicillin, gentamicin, erythromycin and ciprofloxacin. Similar increases in resistance of coagulase-negative staphylococci were reported earlier. 27, 28 Cefamandole and cefazolin were active in vitro against a considerable proportion of the methicillin-resistant coagulase-negative staphylococci, but the clinical relevance of this observation is doubtful. Most laboratories routinely report that methicillin-resistant isolates are resistant to all -lactam antibiotics. The poor response to cephalosporins in endocarditis caused by methicillin-resistant coagulasenegative staphylococci may be due to small resistant subpopulations that are not detected by conventional lowinoculum screening of cephalosporins as practised in the laboratories participating in our surveillance and to their growth in biofilms. 7 Coagulase-negative staphylococci from urine, respiratory tract and faeces were more often resistant to quinolones than isolates from cerebrospinal fluid, blood and skin. The high frequency of resistance in isolates from faeces and urine may be explained by the selective pressure in patients receiving oral antibiotic prophylaxis with quinolones. 29, 30 In a recent European survey, 31 a great difference in resistance to quinolones was found between S. aureus isolated from blood (9%) and urine (34%), which is in line with our observations in coagulase-negative staphylococci.
